ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Oncotarget · 2014 · PMC4196152 · PMID 24952873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

There also was an overall trend for increased ADAM10 expression in the post-neoadjuvant treatment samples (figure 7B , right panel).

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.